147 related articles for article (PubMed ID: 9547133)
1. Moclobemide effects on prolactin plasma levels in healthy individuals: the hormonal increase induced by a single dose is maintained during a 4-week period of drug intake.
Juruena MF; Pires ML; Calil HM
Int Clin Psychopharmacol; 1997 Nov; 12(6):317-21. PubMed ID: 9547133
[TBL] [Abstract][Full Text] [Related]
2. Social phobia: long-term treatment outcome and prediction of response--a moclobemide study.
Versiani M; Amrein R; Montgomery SA
Int Clin Psychopharmacol; 1997 Sep; 12(5):239-54. PubMed ID: 9466158
[TBL] [Abstract][Full Text] [Related]
3. cAMP-dependent phosphorylation system after short and long-term administration of moclobemide.
Mori S; Zanardi R; Popoli M; Garbini S; Brunello N; Smeraldi E; Racagni G; Perez J
J Psychiatr Res; 1998; 32(2):111-5. PubMed ID: 9694007
[TBL] [Abstract][Full Text] [Related]
4. [Preventive treatment of migraine and chronic tension headache with moclobemide].
Meienberg O; Amsler F
Praxis (Bern 1994); 1997 Jul; 86(27-28):1107-12. PubMed ID: 9324719
[TBL] [Abstract][Full Text] [Related]
5. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
Nair NP; Ahmed SK; Kin NM
J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
[TBL] [Abstract][Full Text] [Related]
6. Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide.
Dingemanse J; Hussain Y; Korn A
Int J Clin Pharmacol Ther; 1996 Apr; 34(4):172-7. PubMed ID: 8861736
[TBL] [Abstract][Full Text] [Related]
7. Anxiolytic and memory improving effects of moclobemide.
Nowakowska E; Chodera A; Kus K; Rybakowski J
Arzneimittelforschung; 1998 Jun; 48(6):625-8. PubMed ID: 9689417
[TBL] [Abstract][Full Text] [Related]
8. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
Volz HP; Gleiter CH; Möller HJ
Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
[TBL] [Abstract][Full Text] [Related]
9. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Lavian G; Finberg JP; Youdim MB
Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
[TBL] [Abstract][Full Text] [Related]
10. Effects of long-term treatment with the MAO-A inhibitor moclobemide on sleep EEG and nocturnal hormonal secretion in normal men.
Steiger A; Benkert O; Holsboer F
Neuropsychobiology; 1994; 30(2-3):101-5. PubMed ID: 7800155
[TBL] [Abstract][Full Text] [Related]
11. Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers.
Scheinin M; Koulu M; Karhuvaara S; Zimmer RH
Life Sci; 1990; 47(16):1491-9. PubMed ID: 2250565
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
[TBL] [Abstract][Full Text] [Related]
13. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
14. Light-dark phase differences in behavioral effects of moclobemide in rats.
Górka Z; Zajaczkowski W
Pol J Pharmacol Pharm; 1991; 43(3):177-86. PubMed ID: 1961692
[TBL] [Abstract][Full Text] [Related]
15. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.
Dingemanse J; Guentert T; Gieschke R; Stabl M
J Cardiovasc Pharmacol; 1996 Dec; 28(6):856-61. PubMed ID: 8961085
[TBL] [Abstract][Full Text] [Related]
16. [Selective inhibition of monoamine oxidase in bovine brain by befol and moclobemide].
Moskvitina TA; Gankina EM; Val'dman AV
Vopr Med Khim; 1991; 37(2):49-51. PubMed ID: 1897195
[TBL] [Abstract][Full Text] [Related]
17. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations.
Dingemanse J; Korn A; Pfefen JP; Güntert TW
Psychopharmacology (Berl); 1992; 106 Suppl():S46-8. PubMed ID: 1347659
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
Berlin I; Zimmer R; Thiede HM; Payan C; Hergueta T; Robin L; Puech AJ
Br J Clin Pharmacol; 1990 Dec; 30(6):805-16. PubMed ID: 1705137
[TBL] [Abstract][Full Text] [Related]
19. Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression.
Ramasubbu R
J Psychiatry Neurosci; 1999 Jan; 24(1):45-50. PubMed ID: 9987207
[TBL] [Abstract][Full Text] [Related]
20. [Cholestatic hepatitis associated with the use of moclobemide].
García-Díaz JD; Gila A; Fraguas C; Castillo I
Med Clin (Barc); 1998 Jun; 111(2):77. PubMed ID: 9706594
[No Abstract] [Full Text] [Related]
[Next] [New Search]
